<i>LKB1</i> mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial.

ESMO Open · 2020 · PMC7259832 · PMID 32467099

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

On the other hand, patients with LKB1- mutated tumours treated with erlotinib had worse PFS and OS when compared with patients with LKB1- wt disease (although the observed differences did not reach statistical significance).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.